quinolinic acid has been researched along with Depression, Involutional in 23 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kynurenine pathway, a neuroimmunological pathway plays a substantial role in depression." | 8.12 | Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies. ( Bansal, Y; Bishnoi, M; Dhingra, N; Dhingra, R; Khare, P; Kondepudi, KK; Kuhad, A; Singh, R; Sodhi, RK, 2022) |
| "To investigate the relationship between the tryptophan-kynurenine (TRP-KYN) pathway and painful physical symptoms (PPS) in major depressive disorder (MDD)." | 8.12 | Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder. ( An, H; Bai, L; Fan, H; Ma, B; Ma, T; Qi, S; Wang, Z; Yang, F; Yun, Y; Zhang, Q; Zhao, W, 2022) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 8.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| "Considerable data relate major depressive disorder (MDD) with aberrant immune system functioning." | 5.72 | Peripheral and central kynurenine pathway abnormalities in major depression. ( Asratian, A; Boda, S; Dantzer, R; Erhardt, S; Hamilton, JP; Heilig, M; Holm, L; Kämpe, R; Paul, ER; Samuelsson, M; Schwieler, L; Trepci, A; Yngve, A, 2022) |
| "Kynurenine pathway, a neuroimmunological pathway plays a substantial role in depression." | 4.12 | Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies. ( Bansal, Y; Bishnoi, M; Dhingra, N; Dhingra, R; Khare, P; Kondepudi, KK; Kuhad, A; Singh, R; Sodhi, RK, 2022) |
| "To investigate the relationship between the tryptophan-kynurenine (TRP-KYN) pathway and painful physical symptoms (PPS) in major depressive disorder (MDD)." | 4.12 | Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder. ( An, H; Bai, L; Fan, H; Ma, B; Ma, T; Qi, S; Wang, Z; Yang, F; Yun, Y; Zhang, Q; Zhao, W, 2022) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 4.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| " Evidence suggests that the kynurenine (KYN) pathway may be implicated in the pathophysiology of depression, but few studies have explored the association between the KYN pathway and cognitive impairment in MDD." | 3.91 | Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder. ( Chen, L; Li, H; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2019) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Considerable data relate major depressive disorder (MDD) with aberrant immune system functioning." | 1.72 | Peripheral and central kynurenine pathway abnormalities in major depression. ( Asratian, A; Boda, S; Dantzer, R; Erhardt, S; Hamilton, JP; Heilig, M; Holm, L; Kämpe, R; Paul, ER; Samuelsson, M; Schwieler, L; Trepci, A; Yngve, A, 2022) |
| "The kynurenine pathway has been proposed to play a key role between peripheral inflammation and alterations in the central nervous system." | 1.62 | The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder. ( Aydemir, Ö; Kandemir, H; Öztürk, M; Taneli, F; Yalın Sapmaz, Ş, 2021) |
| "As chronic inflammation is known to precipitate increased apoptosis of neurons and astrocytes, this could be a contributing factor to brain dysfunction." | 1.46 | Major Depression as a Neuroprogressive Prelude to Dementia: What Is the Evidence? ( Leonard, BE, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Bou Khalil, R | 1 |
| El Khoury, R | 1 |
| Paul, ER | 1 |
| Schwieler, L | 1 |
| Erhardt, S | 1 |
| Boda, S | 1 |
| Trepci, A | 1 |
| Kämpe, R | 1 |
| Asratian, A | 1 |
| Holm, L | 1 |
| Yngve, A | 1 |
| Dantzer, R | 7 |
| Heilig, M | 1 |
| Hamilton, JP | 1 |
| Samuelsson, M | 1 |
| Bansal, Y | 1 |
| Singh, R | 1 |
| Sodhi, RK | 1 |
| Khare, P | 1 |
| Dhingra, R | 1 |
| Dhingra, N | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Kuhad, A | 1 |
| Zheng, H | 1 |
| Teague, TK | 7 |
| Yeh, FC | 1 |
| Burrows, K | 1 |
| Figueroa-Hall, LK | 1 |
| Aupperle, RL | 1 |
| Khalsa, SS | 1 |
| Paulus, MP | 1 |
| Savitz, J | 6 |
| Yun, Y | 1 |
| Zhang, Q | 1 |
| Zhao, W | 1 |
| Ma, T | 1 |
| Fan, H | 1 |
| Bai, L | 1 |
| Ma, B | 1 |
| Qi, S | 1 |
| Wang, Z | 1 |
| An, H | 1 |
| Yang, F | 1 |
| Ou, W | 1 |
| Chen, Y | 1 |
| Ju, Y | 1 |
| Ma, M | 1 |
| Qin, Y | 1 |
| Bi, Y | 1 |
| Liao, M | 1 |
| Liu, B | 1 |
| Liu, J | 1 |
| Zhang, Y | 1 |
| Li, L | 1 |
| Öztürk, M | 1 |
| Yalın Sapmaz, Ş | 1 |
| Kandemir, H | 1 |
| Taneli, F | 1 |
| Aydemir, Ö | 1 |
| Cathomas, F | 1 |
| Guetter, K | 1 |
| Seifritz, E | 1 |
| Klaus, F | 1 |
| Kaiser, S | 1 |
| Wurfel, BE | 5 |
| Drevets, WC | 6 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 4 |
| Morris, HM | 3 |
| Savitz, JB | 1 |
| Leonard, BE | 1 |
| Duan, KM | 1 |
| Ma, JH | 1 |
| Wang, SY | 1 |
| Huang, Z | 1 |
| Zhou, Y | 2 |
| Yu, H | 1 |
| Doolin, K | 1 |
| Allers, KA | 1 |
| Pleiner, S | 1 |
| Liesener, A | 1 |
| Farrell, C | 1 |
| Tozzi, L | 1 |
| O'Hanlon, E | 1 |
| Roddy, D | 1 |
| Frodl, T | 1 |
| Harkin, A | 1 |
| O'Keane, V | 1 |
| Zheng, W | 1 |
| Liu, W | 1 |
| Wang, C | 1 |
| Zhan, Y | 1 |
| Li, H | 1 |
| Chen, L | 1 |
| Ning, Y | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Zheng, P | 1 |
| Chen, JJ | 1 |
| Huang, T | 1 |
| Wang, MJ | 1 |
| Wang, Y | 1 |
| Dong, MX | 1 |
| Huang, YJ | 1 |
| Zhou, LK | 1 |
| Xie, P | 1 |
| Smith, CM | 1 |
| Victor, TA | 4 |
| Bellgowan, PS | 2 |
| Bodurka, J | 5 |
| Dahl, J | 1 |
| Andreassen, OA | 1 |
| Verkerk, R | 2 |
| Malt, UF | 1 |
| Sandvik, L | 1 |
| Brundin, L | 1 |
| Ormstad, H | 1 |
| Meier, TB | 2 |
| McIntosh, SA | 1 |
| Young, KD | 1 |
| Van Gool, AR | 1 |
| Fekkes, D | 1 |
| Bannink, M | 1 |
| Sleijfer, S | 1 |
| Kruit, WH | 1 |
| van der Holt, B | 1 |
| Scharpé, S | 1 |
| Eggermont, AM | 1 |
| Stoter, G | 1 |
| Hengeveld, MW | 1 |
| Steiner, J | 1 |
| Walter, M | 1 |
| Gos, T | 1 |
| Guillemin, GJ | 1 |
| Bernstein, HG | 1 |
| Sarnyai, Z | 1 |
| Mawrin, C | 1 |
| Brisch, R | 1 |
| Bielau, H | 1 |
| Meyer zu Schwabedissen, L | 1 |
| Bogerts, B | 1 |
| Myint, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for quinolinic acid and Depression, Involutional
| Article | Year |
|---|---|
The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Topics: Biomarkers; Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Quinolinic A | 2023 |
The role of tryptophan metabolism in postpartum depression.
Topics: Depression; Depression, Postpartum; Depressive Disorder, Major; Female; Humans; Kynurenine; Quinolin | 2018 |
21 other studies available for quinolinic acid and Depression, Involutional
| Article | Year |
|---|---|
δ
Topics: Biomarkers; Depressive Disorder, Major; Heart Rate; Humans; Kynurenine; Quinolinic Acid; Reproducibi | 2021 |
Peripheral and central kynurenine pathway abnormalities in major depression.
Topics: Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Quinolinic Acid | 2022 |
Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies.
Topics: Animals; Antioxidants; Depression; Depressive Disorder, Major; Disease Models, Animal; Humans; Kelch | 2022 |
C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Topics: C-Reactive Protein; Depressive Disorder, Major; Diffusion Tensor Imaging; Humans; Kynurenic Acid; Ky | 2022 |
Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Pain; Quinolinic Acid; Serotonin; Ta | 2022 |
The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder.
Topics: Adolescent; Cross-Sectional Studies; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; | 2021 |
Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder.
Topics: Adult; Case-Control Studies; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Female; H | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Major Depression as a Neuroprogressive Prelude to Dementia: What Is the Evidence?
Topics: Brain; Cytokines; Dementia; Depressive Disorder, Major; Humans; Inflammation; Kynurenine; Oxidative | 2017 |
Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Topics: Adult; Biomarkers; C-Reactive Protein; CA1 Region, Hippocampal; CA2 Region, Hippocampal; CA3 Region, | 2018 |
Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Topics: Adult; Chromatography, Liquid; Cognition; Cross-Sectional Studies; Depression; Depressive Disorder, | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
A novel urinary metabolite signature for diagnosing major depressive disorder.
Topics: Adult; Biomarkers; Case-Control Studies; Depressive Disorder, Major; Dicarboxylic Acids; Discriminan | 2013 |
Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
Topics: Adult; Amygdala; Anhedonia; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Depressive Disord | 2015 |
Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Topics: Adolescent; Adult; Chromatography, Liquid; Depressive Disorder, Major; Female; Humans; Kynurenic Aci | 2015 |
Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.
Topics: Adolescent; Adult; Biomarkers; Chromatography, High Pressure Liquid; Cytokines; Depressive Disorder, | 2015 |
Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder.
Topics: Adult; Anhedonia; Biomarkers; Corpus Striatum; Depressive Disorder, Major; Female; Humans; Kynurenic | 2015 |
Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Topics: Adult; Brain; C-Reactive Protein; Case-Control Studies; Cerebral Cortex; Depressive Disorder, Major; | 2016 |
Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Topics: Adult; Depressive Disorder, Major; Female; Hippocampus; Humans; Kynurenic Acid; Kynurenine; Magnetic | 2016 |
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Topics: Adult; Aged; Brain; Carcinoma, Renal Cell; Depressive Disorder, Major; Dose-Response Relationship, D | 2008 |
Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?
Topics: Adult; Aged; Depressive Disorder, Major; Female; Glutamic Acid; Gyrus Cinguli; Humans; Male; Microgl | 2011 |